Ilia Poliakov1, Cory Toth. 1. Department of Clinical Neurosciences and the University of Calgary, Calgary, Alberta, Canada.
Abstract
Peripheral neuropathy (PN) is a common impairment which may impact upon quality of life (QoL). Neuropathic pain (NeP) occurs in up to 50% of patients with PN. We hypothesized that disability and impaired quality of life resulting from PN is primarily associated with presence of NeP. Our aim was to determine using prospectively identified PN patients presenting to a tertiary care neuromuscular clinic if presence of NeP (PN+NeP) had greater impact upon QoL than with absence of NeP (PN-NeP). A second aim was to identify if QoL varied based upon etiology of PN. We analyzed neuropathy severity (Toronto Clinical Neuropathy Score (TCSS)), pain quantity and quality (Visual Analogue Scale (VAS) pain score, Brief Pain Inventory (BPI)), QoL and health status measures (EuroQol Instrument 5 Domains (EQ-5D), Medical Outcomes Sleep Study Scale (MOSSS), Hospital Anxiety and Depression Scale (HADS), Short Form 36 Health Survey (SF-36)) and Health Assessment Questionnaire (HAQ) to determine impact of NeP. Although both cohorts were epidemiologically similar and had similar severity of PN, PN+NeP patients had considerably greater impairment for QoL, sleep efficacy, and features of anxiety and depression, leading to substantially greater health care resources utilization when compared to PN-NeP patients. The magnitude of NeP severity was the only explaining variable for increased impact upon QoL measures and diminishing overall wellbeing. Our results confirm that NeP is a primary indicator for worsening QoL and diminished overall wellbeing in PN patients. The etiology of PN did not influence levels of NeP-related compromise of QoL. Further studies are needed to determine optimal methods for management of PN+NeP patients subjected to a significant physiological, psychological and functional burden. Copyright Â
Peripheral neuropathy (PN) is a common impairment which may impact upon quality of life (QoL). Neuropathic pain (NeP) occurs in up to 50% of patients with PN. We hypothesized that disability and impaired quality of life resulting from PN is primarily associated with presence of NeP. Our aim was to determine using prospectively identified PN patients presenting to a tertiary care neuromuscular clinic if presence of NeP (PN+NeP) had greater impact upon QoL than with absence of NeP (PN-NeP). A second aim was to identify if QoL varied based upon etiology of PN. We analyzed neuropathy severity (Toronto Clinical Neuropathy Score (TCSS)), pain quantity and quality (Visual Analogue Scale (VAS) pain score, Brief Pain Inventory (BPI)), QoL and health status measures (EuroQol Instrument 5 Domains (EQ-5D), Medical Outcomes Sleep Study Scale (MOSSS), Hospital Anxiety and Depression Scale (HADS), Short Form 36 Health Survey (SF-36)) and Health Assessment Questionnaire (HAQ) to determine impact of NeP. Although both cohorts were epidemiologically similar and had similar severity of PN, PN+NePpatients had considerably greater impairment for QoL, sleep efficacy, and features of anxiety and depression, leading to substantially greater health care resources utilization when compared to PN-NePpatients. The magnitude of NeP severity was the only explaining variable for increased impact upon QoL measures and diminishing overall wellbeing. Our results confirm that NeP is a primary indicator for worsening QoL and diminished overall wellbeing in PN patients. The etiology of PN did not influence levels of NeP-related compromise of QoL. Further studies are needed to determine optimal methods for management of PN+NePpatients subjected to a significant physiological, psychological and functional burden. Copyright Â
Authors: Axel C Mühlbacher; Uwe Junker; Christin Juhnke; Edgar Stemmler; Thomas Kohlmann; Friedhelm Leverkus; Matthias Nübling Journal: Eur J Health Econ Date: 2014-06-21
Authors: David J Kopsky; Ruben P A van Eijk; Janna K Warendorf; Jan M Keppel Hesselink; Nicolette C Notermans; Alexander F J E Vrancken Journal: Trials Date: 2022-10-22 Impact factor: 2.728
Authors: Jamison Falk; Betsy Thomas; Jessica Kirkwood; Christina S Korownyk; Adrienne J Lindblad; Joey Ton; Samantha Moe; G Michael Allan; James McCormack; Scott Garrison; Nicolas Dugré; Karenn Chan; Michael R Kolber; Anthony Train; Liesbeth Froentjes; Logan Sept; Michael Wollin; Rodger Craig; Danielle Perry Journal: Can Fam Physician Date: 2021-05 Impact factor: 3.275
Authors: Peter R Kamerman; Antonia L Wadley; Karen D Davis; Aki Hietaharju; Parmanand Jain; Andreas Kopf; Ana-Claire Meyer; Srinivasa N Raja; Andrew S C Rice; Blair H Smith; Rolf-Detlef Treede; Philip J Wiffen Journal: Pain Date: 2015-05 Impact factor: 7.926
Authors: Nicola Torrance; Janice A Ferguson; Ebenezer Afolabi; Michael I Bennett; Michael G Serpell; Kate M Dunn; Blair H Smith Journal: Pain Date: 2013-01-23 Impact factor: 7.926
Authors: Brigitte A Brouwer; Bianca T A de Greef; Janneke G J Hoeijmakers; Margot Geerts; Maarten van Kleef; Ingemar S J Merkies; Catharina G Faber Journal: Drugs Aging Date: 2015-08 Impact factor: 3.923
Authors: Iyubanit Rodríguez; Valeria Herskovic; Carmen Gerea; Carolina Fuentes; Pedro O Rossel; Maíra Marques; Mauricio Campos Journal: J Med Internet Res Date: 2017-10-27 Impact factor: 5.428